covid-19药物治疗:动态系统评价与网络meta分析
结果显示,在重症患者中,全身性糖皮质激素、白介素-6受体拮抗剂(与糖皮质激素联用)和Janus激酶抑制剂可降低死亡率;在非重症患者中,尼马特雷韦/利托那韦和莫努匹拉韦可能减少住院。
要点
- 重症covid-19患者中,全身性糖皮质激素、白介素-6受体拮抗剂(联用糖皮质激素)和Janus激酶抑制剂可降低死亡率。
- 非重症covid-19患者中,尼马特雷韦/利托那韦和莫努匹拉韦可能减少住院风险。
- 莫努匹拉韦是唯一有至少中等质量证据显示可缩短症状缓解时间的药物。
核心结论
- 在重症covid-19患者中,全身性糖皮质激素、白介素-6受体拮抗剂和Janus激酶抑制剂可能降低死亡率并带来其他重要获益。
- 在非重症covid-19患者中,莫努匹拉韦和尼马特雷韦/利托那韦可能减少住院。
研究设计与样本
- 采用贝叶斯网络meta分析,使用改良Cochrane偏倚风险评估工具2.0评估偏倚风险,采用GRADE方法评估证据确定性。
主要发现
- 与标准治疗相比,全身性糖皮质激素降低死亡率(每1000例减少23例,95%可信区间减少40至7例,中等确定性)。
- 与标准治疗相比,白介素-6受体拮抗剂联用糖皮质激素降低死亡率(每1000例减少23例,95%可信区间减少36至7例,中等确定性)。
- 与标准治疗相比,Janus激酶抑制剂降低死亡率(每1000例减少44例,95%可信区间减少64至20例,高确定性)。
- 与标准治疗相比,尼马特雷韦/利托那韦减少非重症患者住院(每1000例减少36例,95%可信区间减少41至26例,中等确定性)。
- 与标准治疗相比,莫努匹拉韦减少非重症患者住院(每1000例减少19例,95%可信区间减少29至5例,中等确定性),并缩短症状缓解时间(减少3.3天,95%可信区间减少4.8至1.6天,中等确定性)。
关键数值与推荐
- 全身性糖皮质激素:每1000例减少23例死亡(95%可信区间减少40至7例),中等确定性。
- 白介素-6受体拮抗剂联用糖皮质激素:每1000例减少23例死亡(95%可信区间减少36至7例),中等确定性。
- Janus激酶抑制剂:每1000例减少44例死亡(95%可信区间减少64至20例),高确定性。
- 尼马特雷韦/利托那韦:每1000例减少36例住院(95%可信区间减少41至26例),中等确定性。
- 莫努匹拉韦:每1000例减少19例住院(95%可信区间减少29至5例),中等确定性;症状缓解时间减少3.3天(95%可信区间减少4.8至1.6天)。
临床怎么用
- 对重症covid-19患者,可考虑使用全身性糖皮质激素、白介素-6受体拮抗剂(与糖皮质激素联用)或Janus激酶抑制剂以降低死亡率。
- 对非重症covid-19患者,可考虑使用尼马特雷韦/利托那韦或莫努匹拉韦以减少住院风险。
- 需注意部分药物可能增加导致停药的不良反应风险,羟氯喹可能增加机械通气风险(中等确定性)。
局限性
- 本系统评价未注册。
- 证据确定性因药物和结局而异,部分为低确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effects of treatments for coronavirus disease 2019 (covid-19). DESIGN: Living systematic review and network meta-analysis. DATA SOURCES: WHO covid-19 database, a comprehensive multilingual source of global covid-19 literature, up to 3 December 2021 and six additional Chinese databases up to 20 February 2021. Studies identified as of 1 December 2021 were included in the analysis. STUDY SELECTION: Randomised clinical trials in which people with suspected, probable, or confirmed covid-19 were randomised to drug treatment or to standard care or placebo. Pairs of reviewers independently screened potentially eligible articles. METHODS: After duplicate data abstraction, a bayesian network meta-analysis was conducted. Risk of bias of the included studies was assessed using a modification of the Cochrane risk of bias 2.0 tool, and the certainty of the evidence using the grading of recommendations assessment, development, and evaluation (GRADE) approach. For each outcome, interventions were classified in groups from the most to the least beneficial or harmful following GRADE guidance. RESULTS: 463 trials enrolling 166 581 patients were included; 267 (57.7%) trials and 89 814 (53.9%) patients are new from the previous iteration; 265 (57.2%) trials evaluating treatments with at least 100 patients or 20 events met the threshold for inclusion in the analyses. Compared with standard care, three drugs reduced mortality in patients with mostly severe disease with at least moderate certainty: systemic corticosteroids (risk difference 23 fewer per 1000 patients, 95% credible interval 40 fewer to 7 fewer, moderate certainty), interleukin-6 receptor antagonists when given with corticosteroids (23 fewer per 1000, 36 fewer to 7 fewer, moderate certainty), and Janus kinase inhibitors (44 fewer per 1000, 64 fewer to 20 fewer, high certainty). Compared with standard care, two drugs probably reduce hospital admission in patients with non-severe disease: nirmatrelvir/ritonavir (36 fewer per 1000, 41 fewer to 26 fewer, moderate certainty) and molnupiravir (19 fewer per 1000, 29 fewer to 5 fewer, moderate certainty). Remdesivir may reduce hospital admission (29 fewer per 1000, 40 fewer to 6 fewer, low certainty). Only molnupiravir had at least moderate quality evidence of a reduction in time to symptom resolution (3.3 days fewer, 4.8 fewer to 1.6 fewer, moderate certainty); several others showed a possible benefit. Several drugs may increase the risk of adverse effects leading to drug discontinuation; hydroxychloroquine probably increases the risk of mechanical ventilation (moderate certainty). CONCLUSION: Corticosteroids, interleukin-6 receptor antagonists, and Janus kinase inhibitors probably reduce mortality and confer other important benefits in patients with severe covid-19. Molnupiravir and nirmatrelvir/ritonavir probably reduce admission to hospital in patients with non-severe covid-19. SYSTEMATIC REVIEW REGISTRATION: This review was not registered. The protocol is publicly available in the supplementary material. READERS' NOTE: This article is a living systematic review that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication. This is the fifth version of the original article published on 30 July 2020 (BMJ 2020;370:m2980), and previous versions can be found as data supplements. When citing this paper please consider adding the version number and date of access for clarity.
引用
- Siemieniuk RA, Bartoszko JJ, Zeraatkar D, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020. PMID: 32732190. doi:10.1136/bmj.m2980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。